1501 related articles for article (PubMed ID: 20143189)
21. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.
Han K; Nofech-Mozes S; Narod S; Hanna W; Vesprini D; Saskin R; Taylor C; Kong I; Paszat L; Rakovitch E
Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):183-9. PubMed ID: 21958729
[TBL] [Abstract][Full Text] [Related]
22. Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in situ, and adjacent normal epithelium.
Oliveira VM; Piato S; Silva MA
Breast Cancer Res Treat; 2006 Feb; 95(3):235-41. PubMed ID: 16322898
[TBL] [Abstract][Full Text] [Related]
23. Scintimammographic detection of usual ductal breast hyperplasia with increased proliferation rate at risk for malignancy.
Papantoniou V; Tsiouris S; Koutsikos J; Sotiropoulou M; Mainta E; Lazaris D; Valsamaki P; Melissinou M; Zerva C; Antsaklis A
Nucl Med Commun; 2006 Nov; 27(11):911-7. PubMed ID: 17021432
[TBL] [Abstract][Full Text] [Related]
24. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness.
Wärnberg F; Nordgren H; Bergkvist L; Holmberg L
Br J Cancer; 2001 Sep; 85(6):869-74. PubMed ID: 11556839
[TBL] [Abstract][Full Text] [Related]
25. Breast carcinoma in women 35 years and younger: a pathological study.
Fernandopulle SM; Cher-Siangang P; Tan PH
Pathology; 2006 Jun; 38(3):219-22. PubMed ID: 16753742
[TBL] [Abstract][Full Text] [Related]
26. Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters.
Naidu R; Wahab NA; Yadav MM; Kutty MK
Oncol Rep; 2002; 9(2):409-16. PubMed ID: 11836618
[TBL] [Abstract][Full Text] [Related]
27. CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
Bircan S; Kapucuoglu N; Baspinar S; Inan G; Candir O
Pathol Res Pract; 2006; 202(8):569-76. PubMed ID: 16828238
[TBL] [Abstract][Full Text] [Related]
28. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).
von Minckwitz G; Darb-Esfahani S; Loibl S; Huober J; Tesch H; Solbach C; Holms F; Eidtmann H; Dietrich K; Just M; Clemens MR; Hanusch C; Schrader I; Henschen S; Hoffmann G; Tiemann K; Diebold K; Untch M; Denkert C
Breast Cancer Res Treat; 2012 Apr; 132(3):863-70. PubMed ID: 21667238
[TBL] [Abstract][Full Text] [Related]
29. Vasohibin-1 as a potential predictor of aggressive behavior of ductal carcinoma in situ of the breast.
Tamaki K; Sasano H; Maruo Y; Takahashi Y; Miyashita M; Moriya T; Sato Y; Hirakawa H; Tamaki N; Watanabe M; Ishida T; Ohuchi N
Cancer Sci; 2010 Apr; 101(4):1051-8. PubMed ID: 20704578
[TBL] [Abstract][Full Text] [Related]
30. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone.
Cornfield DB; Palazzo JP; Schwartz GF; Goonewardene SA; Kovatich AJ; Chervoneva I; Hyslop T; Schwarting R
Cancer; 2004 Jun; 100(11):2317-27. PubMed ID: 15160334
[TBL] [Abstract][Full Text] [Related]
31. Imaging in situ breast carcinoma (with or without an invasive component) with technetium-99m pentavalent dimercaptosuccinic acid and technetium-99m 2-methoxy isobutyl isonitrile scintimammography.
Papantoniou V; Tsiouris S; Mainta E; Valotassiou V; Souvatzoglou M; Sotiropoulou M; Nakopoulou L; Lazaris D; Louvrou A; Melissinou M; Tzannetaki A; Pirmettis I; Koutsikos J; Zerva C
Breast Cancer Res; 2005; 7(1):R33-45. PubMed ID: 15642168
[TBL] [Abstract][Full Text] [Related]
32. Correlation between uptake of Tc-99m sestaMIBI and prognostic factors of breast cancer.
Cwikla JB; Buscombe JR; Kolasinska AD; Parbhoo SP; Thakrar DS; Hilson AJ
Anticancer Res; 1999; 19(3B):2299-304. PubMed ID: 10472348
[TBL] [Abstract][Full Text] [Related]
33. Oestrogen-induced genes in ductal carcinoma in situ: their comparison with invasive ductal carcinoma.
Ebata A; Suzuki T; Takagi K; Miki Y; Onodera Y; Nakamura Y; Fujishima F; Ishida K; Watanabe M; Tamaki K; Ishida T; Ohuchi N; Sasano H
Endocr Relat Cancer; 2012 Aug; 19(4):485-96. PubMed ID: 22569827
[TBL] [Abstract][Full Text] [Related]
34. Impact of estrogen receptor expression and other clinicopathologic features on tamoxifen use in ductal carcinoma in situ.
Hird RB; Chang A; Cimmino V; Diehl K; Sabel M; Kleer C; Helvie M; Schott A; Young J; Hayes D; Newman L
Cancer; 2006 May; 106(10):2113-8. PubMed ID: 16596655
[TBL] [Abstract][Full Text] [Related]
35. Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component.
Yu KD; Wu LM; Liu GY; Wu J; Di GH; Shen ZZ; Shao ZM
Ann Surg Oncol; 2011 May; 18(5):1342-8. PubMed ID: 21042943
[TBL] [Abstract][Full Text] [Related]
36. Grade of ductal carcinoma in situ accompanying infiltrating ductal carcinoma as an independent prognostic factor.
Kim JY; Han W; Moon HG; Park IA; Ahn SK; Kim J; Lee JW; Kim T; Kim MK; Noh DY
Clin Breast Cancer; 2013 Oct; 13(5):385-91. PubMed ID: 23870857
[TBL] [Abstract][Full Text] [Related]
37. Concomitant expression of epithelial-mesenchymal transition biomarkers in breast ductal carcinoma: association with progression.
Logullo AF; Nonogaki S; Pasini FS; Osório CA; Soares FA; Brentani MM
Oncol Rep; 2010 Feb; 23(2):313-20. PubMed ID: 20043090
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathological significance of CADM4 expression in invasive ductal carcinoma of the breast.
Jang SM; Sim J; Han H; Ahn HI; Kim H; Yi K; Jun YJ; Rehman A; Chung MS; Jang K; Paik SS
J Clin Pathol; 2013 Aug; 66(8):681-6. PubMed ID: 23559354
[TBL] [Abstract][Full Text] [Related]
39. The routine immunohistochemical evaluation in Paget disease of the nipple.
Marczyk E; Kruczak A; Ambicka A; Mularz K; Harazin-Lechowska A; Moskal J; Sokołowski A; Mituś J; Ryś J
Pol J Pathol; 2011 Dec; 62(4):229-35. PubMed ID: 22246908
[TBL] [Abstract][Full Text] [Related]
40. [Expression and significance of phosphorylated Girdin in breast cancer].
Xu Y; Fu L; Gu F; Ma YJ
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):205-9. PubMed ID: 22780975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
